Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,301–2,400 of 4,628
Zhang, B., Gao, D., Xu, G., Zhu, W., Liu, J., Sun, R., Wang, L., Zhang, C., Ding, Q., & Shi, Y. (2022) · Phytochemical Analysis · doi:10.1002/pca.3120 · Cited by 10
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 13
Barešić, M., Novak, S., Perković, D., Karanović, B., Mirić, F., Radić, M., & Anić, B. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06689-3 · Cited by 10
Kim, K. H., Lim, S. M., Ahn, H. K., Lee, Y., Lee, K., Ahn, M., Keam, B., Kim, H. R., Lee, H. W., An, H. J., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.433 · Cited by 10
CD4+LAG3+T cells are decreased in SSc-ILD and affect fibroblast mesenchymal transition by TGF-β3
Qin, L., Lin, H., Zhu, F., Wang, J., Feng, T., Xu, T., Zhang, G., & Zhang, X. (2023) · iScience · doi:10.1016/j.isci.2023.108225 · Cited by 11
Enomoto, N. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.03.006 · Cited by 14
A roadmap to precision treatments for familial pulmonary fibrosis
Hurley, K., Ozaki, M., Philippot, Q., Galvin, L., Crosby, D., Kirwan, M., Gill, D. R., Alysandratos, K., Jenkins, G. R., Griese, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105135 · Cited by 11
Promising advances in treatments for the management of idiopathic pulmonary fibrosis
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354460 · Cited by 11
Self-citationWeng, C., Zhou, Y., Zhang, L., Wang, G., Ding, Z., Xue, L., & Liu, Z. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152500 · Cited by 10
Pulmonary rehabilitation in idiopathic pulmonary fibrosis
Dowman, L., & Holland, A. E. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001094 · Cited by 12
Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis
Lauer, D., Magnin, C., Kolly, L. R., Wang, H., Brunner, M., Chabria, M., Cereghetti, G. M., Gabryś, H. S., Tanadini‐Lang, S., Uldry, A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.181757 · Cited by 11
Acute exacerbations in patients with progressive pulmonary fibrosis
Kreuter, M., Belloli, E. A., Bendstrup, E. M., Cerri, S., Flaherty, K. R., Shapera, S., Song, J. W., Mueller, H., Rohr, K. B., Kondoh, Y., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00403-2024 · Cited by 20
Self-citationTanshinone IIA Loaded Inhaled Polymer Nanoparticles Alleviate Established Pulmonary Fibrosis
Chen, W., Gao, Y., Liu, Y., Luo, Y., Xue, X., Xiao, C., & Wei, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00532 · Cited by 10
Li, A., Teoh, A. K. Y., Troy, L. K., Glaspole, I., WILSHER, M. L., de Boer, S., Wrobel, J. P., Moodley, Y. P., Thien, F. C. K., Gallagher, H., et al. (2024) · Thorax · doi:10.1136/thorax-2024-221813 · Cited by 12
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
Harari, S. A., Elia, D., Caminati, A., Geginat, J., Luisi, F., Pelosi, G., Specchia, C., Torre, O., Trevisan, R., Vasco, C., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00217-0 · Cited by 12
The role of TRP channels in lung fibrosis: Mechanisms and therapeutic potential
Ratnasingham, M., Bradding, P., & Roach, K. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106728 · Cited by 11
Wuyts, W. A., Bonella, F., Chaudhuri, N., Varone, F., Antin-Ozerkis, D. E., Song, J. W., Miede, C., Dumistracel, M., Coeck, C., & Cottin, V. (2025) · Lung · doi:10.1007/s00408-024-00778-z · Cited by 14
Self-citationBirker, M., Boucher, M., Ranieri, G., Poirey, S., Studer, R. O., Freti, D., Schnoebelen, M., Froidevaux, S., Morrison, K., Wyss, C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103396 · Cited by 12
Takashima, T., Zeng, C., Murakami, E., Fujiwara, N., Kohara, M., Nagata, H., Feng, Z., Sugai, A., Harada, Y., Ichijo, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187172 · Cited by 12
A Comprehensive Review of Interstitial Lung Abnormalities
Moodley, Y. P., & Mackintosh, J. A. (2025) · Respirology · doi:10.1111/resp.70026 · Cited by 10
“This compares to an annual decline in FVC of approximately 240 mL in the placebo arms of the pivotal nintedanib phase 3 trials [54].”
Aono, Y., Nakamura, Y., Kono, M., Nakamura, H., Yokomura, K., Imokawa, S., Toyoshima, M., Yasui, H., Hozumi, H., Karayama, M., et al. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620953783 · Cited by 12
Abe, M., Tsushima, K., Ishii, D., Shikano, K., Yoshioka, K., Sakayori, M., Suzuki, M., Hirasawa, Y., Ishiwata, T., Kawasaki, T., et al. (2021) · Advances in respiratory medicine · doi:10.5603/arm.a2021.0012 · Cited by 12
Interstitial Lung Diseases and the Impact of Gender
Karampitsakos, Τ., Παπαϊωάννου, Ο., Katsaras, M., Sampsonas, F., & Τzouvelekis, Α. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.04.011 · Cited by 10
COVID-related fibrosis: insights into potential drug targets
Sgalla, G., Comes, A., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2010188 · Cited by 12
Self-citationCarr, Z. J., Yan, L., Chavez-Duarte, J., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 10
An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis
Murthy, P., Shaibie, N. A., Lim, C. L., Ling, A. P. K., Chye, S. M., & Koh, R. Y. (2022) · Processes · doi:10.3390/pr10061131 · Cited by 11
Huang, T., & He, W.-Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.890530 · Cited by 10
“Nevertheless, although these two drugs can slightly reduce the number of people with lung function deterioration, they can neither significantly prevent the disease progression nor reduce the mortality of IPF patients (King et al., 2014b; Richeldi et al., 2014; Raghu et al., 2015), making IPF the disease with the wors…”
BackgroundPregnancy Considerations for Patients With Interstitial Lung Disease
Grant-Orser, A., Metcalfe, A., Pope, J. E., & Johannson, K. A. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.024 · Cited by 11
Májek, O., Gregor, J., Moğulkoç, N., Lewandowska, K. B., Šterclová, M., Müller, V., Hájková, M., Kramer, M. R., Tekavec-Trkanjec, J., Jovanović, D. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273854 · Cited by 11
Gu, J., Wu, Q., Zhang, Q., You, Q., & Wang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114742 · Cited by 12
Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury
van Gijsel‐Bonnello, M., Darling, N. J., Tanaka, T., Carmine, S. D., Marchesi, F., Thomson, S. M., Clark, K., Kurowska‐Stolarska, M., McSorley, H. J., Cohen, P., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102644 · Cited by 12
“We show here that loss of SIK2 activity protects against bleomycin-induced lung fibrosis in mice, and that the clinically approved IPF drug nintedanib is a potent inhibitor of SIK2.”
BackgroundInfluentialVISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis
Kim, S., Adams, T. S., Hu, Q., Shin, H. J., Chae, G., Lee, S. E., Sharma, L., Kwon, H., Lee, F. Y., Park, H., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0219oc · Cited by 9
Deciphering the Antifibrotic Property of Metformin
Septembre‐Malaterre, A., Boina, C., Douanier, A., & Gasque, P. (2022) · Cells · doi:10.3390/cells11244090 · Cited by 12
Sarkar, A., Das, S., Bone, H., DeVengencie, I., Prasad, J. M. N., Farkas, D., Londino, J. D., Nho, R. S., Rojas, M. M., & Horowitz, J. C. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200511 · Cited by 9
Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease
Berger, K., & Kaner, R. J. (2023) · Life · doi:10.3390/life13030599 · Cited by 12
“Subsequently, the phase II randomized trial INJOURNEY investigated the combination therapy of nintedanib plus pirfenidone versus nintedanib monotherapy.”
BackgroundInfluentialQing, K., Altes, T. A., Mugler, J. P., Mata, J. F., Tustison, N. J., Ruppert, K., Bueno, J., Flors, L., Shim, Y. M., Zhao, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061533 · Cited by 11
“Nindetanib and pirfenidone [7,8] reduce the rate of progression in lung function decline and may improve mortality in IPF [9], but it is not known whether they are more or less effective in specific subsets of patients.”
BackgroundZhao, M., Ding, N., Wang, H., Zu, S., Liu, H., Wen, J., Liu, J., Ge, N., Wang, W., & Zhang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119501 · Cited by 10
“Thus, therapies that target this mechanism may have the potential to prevent fibrosis progression and perhaps even reverse established bladder fibrosis, as suggested by studies in other tissues [43,44].”
BackgroundApproach to Clinical Trials for the Prevention of Pulmonary Fibrosis
Kim, J. S., Montesi, S. B., Adegunsoye, A., Humphries, S. M., Salisbury, M. L., Hariri, L. P., Kropski, J. A., Richeldi, L., Wells, A. U., Walsh, S. L. F., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202303-188ps · Cited by 11
Self-citationToward targeted treatments for silicosis
Barnes, H., Lam, M., Tate, M. D., & Hoy, R. F. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001020 · Cited by 11
Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis
Zhu, X., Ji, J., & Han, X. (2023) · Journal of Molecular Histology · doi:10.1007/s10735-023-10169-y · Cited by 12
Duke, J. D., Roy, M., Daley, S., Hoult, J. P., Benzo, R., & Moua, T. (2024) · ERJ Open Research · doi:10.1183/23120541.00591-2023 · Cited by 12
Therapeutic Strategies for Idiopathic Pulmonary Fibrosis – Thriving Present and Promising Tomorrow
Gupta, N., Paryani, M., Patel, S. S., Bariya, A. H., Srivastava, A., Pathak, Y. V., & Butani, S. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2408 · Cited by 11
Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis
Li, Y., Jiang, C., Zhu, W., Lu, S., Yu, H., & Meng, L. (2024) · Science Progress · doi:10.1177/00368504241247402 · Cited by 11
TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis
Whalen, W., Berger, K., Kim, J. S., Simmons, W., Ma, S., Kaner, R. J., Martínez, F. J., Anstrom, K. J., Parfrey, H., Maher, T. M., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2224le · Cited by 12
Orphan drug approvals of 2014: Europe and the United States
Norman, P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1022530 · Cited by 10
Update in Diffuse Parenchymal Lung Disease 2013
Rosas, I. O., & Kaminski, N. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0856up · Cited by 12
Idiopathic pulmonary fibrosis: an Australian perspective
Prasad, J. D., Holland, A. E., Glaspole, I., & Westall, G. P. (2016) · Internal Medicine Journal · doi:10.1111/imj.13078 · Cited by 13
Idiopathic pulmonary fibrosis: current and future directions
Soo, E., Adamali, H. I., & Edey, A. (2017) · Clinical Radiology · doi:10.1016/j.crad.2016.12.014 · Cited by 11
Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis
Surasarang, S. H., Florova, G., Komissarov, A. A., Shetty, S., Idell, S., & Williams, R. O. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1371736 · Cited by 10
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre
Guler, S. A., Zumstein, P., Berezowska, S., Pöllinger, A., Geiser, T., & Funke-Chambour, M. (2018) · Swiss Medical Weekly · doi:10.4414/smw.2018.14577 · Cited by 10
Arizono, S., Taniguchi, H., Sakamoto, K., Kondoh, Y., Kimura, T., Kataoka, K., Ogawa, T., Watanabe, F., Tabira, K., & Kozu, R. (2017) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v34i4.5549 · Cited by 11
Self-citationBrownback, K. R., Pitts, L. R., & Abhyankar, S. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0182-9 · Cited by 10
Rasky, A. J., Habiel, D. M., Morris, S. B., Schaller, M. A., Moore, B. B., Phan, S. H., Kunkel, S. L., Phillips, M., Hogaboam, C. M., & Lukacs, N. W. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00114.2019 · Cited by 11
Cheng, W., Wang, F., Feng, A., Li, X., & Yu, W. (2020) · BioMed Research International · doi:10.1155/2020/7840652 · Cited by 10
“In 2014, the US Food and Drug Administration(FDA-) approved nintedanib [2] and pirfenidone [3] may slow down the decline in lung function in patients with IPF but cannot change the IPF survival rate.”
BackgroundSuehs, C., BOURDIN, A. A., Vachier, I., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2814 · Cited by 10
Toi, Y., Kimura, Y., Domeki, Y., Kawana, S., Aiba, T., Ono, H., Aso, M., Tsurumi, K., Suzuki, K., Shimizu, H., et al. (2019) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v36i1.7383 · Cited by 10
Oxygen for interstitial lung diseases
Khor, Y. H., Smith, D. J. F., Johannson, K. A., & Renzoni, E. A. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000691 · Cited by 12
Xia, Y., Lei, C., Yang, D., & Luo, H. (2020) · PeerJ · doi:10.7717/peerj.9848 · Cited by 11
“However, these treatments merely slow the progression of IPF, without improving lung function (Costabel et al., 2019; Costabel et al., 2017; Richeldi et al., 2014; Richeldi et al., 2020).”
BackgroundQiu, Y., Wang, Z., Zhang, X., Huang, P., Zhang, W., Zhang, K., Wang, S., He, L., Guo, Y., An, X., et al. (2020) · IUBMB Life · doi:10.1002/iub.2389 · Cited by 11
“The first, nintedanib, is a multityrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).(7) However, due to its poor oral bioavailability, as well as the side effects caused by off-…”
BackgroundWhat parameters can be used to identify early idiopathic pulmonary fibrosis?
Mori, Y., & Kondoh, Y. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.008 · Cited by 13
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib
Ameri, P., Tini, G., Spallarossa, P., Mercurio, V., Tocchetti, C. G., & Porto, I. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14793 · Cited by 12
Kim, G. H. J., Shi, Y., Yu, W., & Wong, W. K. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106333 · Cited by 12
A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis
Blackwell, T. S., Hewlett, J. C., Mason, W. R., Martin, S., Greco, J. D., Ding, G., Wu, P., LANCASTER, L. H., Loyd, J. E., Dudenhofer, R. B., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-108oc · Cited by 11
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931119 · Cited by 13
Self-citationMicellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis
Skurikhin, Е. G., Мадонов, П. Г., Pershina, О. V., Ermakova, N. N., Pakhomova, A. V., Widera, D., Pan, E. S., Zhukova, М. А., Sandrikina, L. A., Artamonov, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115599 · Cited by 13
Rethinking Idiopathic Pulmonary Fibrosis
Oldham, J. M., & Vancheri, C. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.005 · Cited by 13
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Kang, J., & Song, J. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-97396-z · Cited by 12
Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
Bourne, M. H., Kottom, T. J., Hebrink, D. M., Choudhury, M., Leof, E. B., & LIMPER, A. H. (2021) · Cells · doi:10.3390/cells10123502 · Cited by 10
Usual interstitial pneumonia: a clinically significant pattern, but not the final word
Larsen, B. T. (2022) · Modern Pathology · doi:10.1038/s41379-022-01054-2 · Cited by 10
Choudhary, R., Kumar, A., Ali, O., & Pervez, A. (2022) · Cureus · doi:10.7759/cureus.29435 · Cited by 15
“There is currently very little available dahe actual experience of antifibrotic medicines in patients with PF [7-9].”
BackgroundSu, X., Tan, Z., Wang, G., Liu, Z., Gan, C., Yue, L., Liu, H., Xie, Y., Yao, Y., & Ye, T. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114918 · Cited by 13
Oruqaj, G., Karnati, S., Kotarkonda, L. K., Boateng, E., Bartkuhn, M., Zhang, W., Ruppert, C., Günther, A., Bartholin, L., Shi, W., et al. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.11.006 · Cited by 14
Sabater, L., Gossart, J. B., Hernandez, I., Rico, D., Blanchard, A. D., Borthwick, L. A., Fisher, A. J., Majo, J., Jiwa, K., Collins, A., et al. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.12.015 · Cited by 11
Bendstrup, E. M., Hyldgaard, C., Altraja, A., Sjåheim, T., Myllärniemi, M., Guðmundsson, G., Sköld, M. C., & Hilberg, O. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.28348 · Cited by 12
Confluent fibrosis and fibroblast foci in fibrotic non‐specific interstitial pneumonia
Churg, A., & Bilawich, A.-M. (2016) · Histopathology · doi:10.1111/his.12950 · Cited by 10
Hosein, K., Le, J., & Mura, M. (2016) · Lung · doi:10.1007/s00408-016-9963-3 · Cited by 12
Koegelenberg, C. F. N., Ainslie, G., Dheda, K. U. J., Allwood, B., Wong, M., Lalloo, U., Abdool-Gaffar, M. S., Khalfey, H., & Irusen, E. M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.05 · Cited by 10
Integrated Transitions of Care for Patients With Rare Pulmonary Diseases
Moreo, K., Lattimer, C., Lett, J. E., Heggen, C. L., & Simone, L. (2017) · Professional Case Management · doi:10.1097/ncm.0000000000000198 · Cited by 12
Mooney, J. J., & Collard, H. R. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.08.1172 · Cited by 10
Self-citationIdiopathic pulmonary fibrosis: A guide for nurse practitioners
Vega‐Olivo, M., & Criner, G. J. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000531121.07294.36 · Cited by 11
Tuyls, S., Verleden, S. E., Wuyts, W. A., Yserbyt, J., Vos, R., & Verleden, G. M. (2018) · Transplant International · doi:10.1111/tri.13382 · Cited by 10
Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis
Aussedat, P. H., Chebib, N., Ahmad, K., Glérant, J., Drevet, G., Grima, R., Maury, J., Nasser, M., Thivolet-Béjui, F., Traclet, J., et al. (2020) · Respiration · doi:10.1159/000509557 · Cited by 11
Self-citationMari, P., Wells, A. U., & Richeldi, L. (2019) · doi:10.1183/9781849840798.010518 · Cited by 11
Self-citationAcute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage
Hambly, N., Cox, G., & Kolb, M. R. J. (2017) · European Respiratory Journal · doi:10.1183/13993003.00811-2017 · Cited by 11
Self-citationAmbulatory and short-burst oxygen for interstitial lung disease
Sharp, C., Adamali, H. I., & Millar, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011716 · Cited by 10
Caveolin-1-Derived Peptide Reduces ER Stress and Enhances Gelatinolytic Activity in IPF Fibroblasts
Komatsu, S., Fan, L., Idell, S., Shetty, S., & Ikebe, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063316 · Cited by 10
Maher, T. M., Goldin, J. G., Hood, J., Pitman, J., de los Rios, M., Hobbs, B. P., Yu-Lin, A. B., Buendia-Roldan, I., Thien, F., Song, J. W., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00239-5 · Cited by 9
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
Wei, Y., Hou, J., Lü, P., Fu, L., Wang, X., Huang, Y. L., Chen, L., & Lv, C. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132012 · Cited by 9
Okuno, D., Sakamoto, N., Akiyama, Y., et al. (2022) · Cells · doi:10.3390/cells11182816 · Cited by 9
Urteaga, M. B., Ruz, J. R., & González, M. S. (2022) · Radiología · doi:10.1016/j.rx.2022.10.009 · Cited by 13
AT2 cell–derived IgA trapped by the extracellular matrix in silica-induced pulmonary fibrosis
Chen, M., Wang, J., Yuan, M., Min, L., Sun, Y., Wang, S., Luo, W. F., Zhou, Y., Zhang, W., Jiang, W., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110545 · Cited by 10
Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway
Lai, X., Lin, Y., Huang, S., Pu, L., Zeng, Q., Wang, Z., & Huang, W. (2023) · Respiratory Research · doi:10.1186/s12931-023-02513-3 · Cited by 10
Murgo, A., Bignami, F., Federico, G., Villetti, G., Civelli, M., Sala, A., & Miglietta, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303646 · Cited by 13
Maher, T. M., Brown, K. K., Cunningham, S., DeBoer, E. M., Deterding, R. R., Fiorino, E. K., Griese, M., Schwerk, N., Warburton, D., Young, L. R., et al. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26882 · Cited by 11
Self-citationCircular RNAs and their roles in idiopathic pulmonary fibrosis
Surendran, A. M., Huang, C., & Liu, L. (2024) · Respiratory Research · doi:10.1186/s12931-024-02716-2 · Cited by 14
Selvan, K. C., Reicher, J. J., Muelly, M. C., Kalra, A., & Adegunsoye, A. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03021-w · Cited by 11
Sun, X., Wang, H., Zhan, X., Yan, Y., Chen, K., An, Z., & Zhou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1256649 · Cited by 9
Neoblast-like stem cells of Fasciola hepatica
McCusker, P., Clarke, N., Gardiner, E., Armstrong, R., Mccammick, E. M., McVeigh, P., Robb, E., Wells, D., Nowak-Roddy, M., Albaqami, A., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011903 · Cited by 10
Madsen, S. F., Madsen, S., Madrid, A. S., Andersen, M. R., Bay‐Jensen, A., & Thudium, C. S. (2024) · Translational Medicine Communications · doi:10.1186/s41231-024-00180-0 · Cited by 11
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.